Lymphocyte Markers As Predictors Of Responsiveness To Rituximab Among Patients With Idiopathic Nephrotic Syndrome
NCT03501459
·
clinicaltrials.gov ↗
PHASE3
Phase
UNKNOWN
Status
100
Enrollment
OTHER
Sponsor class
Conditions
Nephrotic Syndrome
Interventions
DRUG:
Rituximab
Sponsor
National University Health System, Singapore